Mandate

Vinge has advised Xpray Pharma in connection with share issue

November 08, 2021 Capital Markets and Public M&A

Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of approximately SEK 100 million.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström and Joel Magnusson.

Related

Vinge advises Stendörren in connection with issuance of green capital securities

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Fazer in connection with its acquisition of Aroma

Fazer has entered into an agreement to acquire Konfektyrfabriken Aroma AB, a Swedish confectionery manufacturer known for its classic candy products such as Geléhallon, Hallonbåtar, Röda Hjärtan and Gräddkola. The acquisition strengthens Fazer's position in the Swedish confectionery market, particularly within pick & mix, packed candy, and seasonal products. The acquisition is subject to customary regulatory approvals.
May 06, 2026